If VK5211 data is positive, I think they are highly likely to receive a partnership offer to not just commercialize it (post p3) in hip but also to expand trials in the other indications you mention. This will set a higher share price base before liver data is due in 1H18.
As for me, I'm super excited about the hip data itself, which can come any time this quarter.
Lol Greens, well said! Really happy to be going into news with these recent levels and volumes traded. I wonder if ligand would ever increase their stake if data looked good. Partnership opps shouldn't really be impacted if they did. They already have quite a stake in the drug anyways by virtue of their holdings.
News 
Market Data 
Discover 
